India, Nov. 17 -- Shares of SELLAS Life Sciences Group, Inc. (SLS) are surging today after the company reported positive results from the Phase 3 REGAL trial of its cancer vaccine candidate, Galinpepimut-S (GPS).
The Phase 3 REGAL trial evaluated Galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, as maintenance monotherapy in acute myeloid leukemia patients who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.
The REGAL trial met its primary endpoint of overall survival (OS). GPS significantly improved OS compare...